Department of Biochemistry and Molecular Biology, University of New Mexico, School of Medicine, Albuquerque, New Mexico, United States of America.
PLoS One. 2012;7(3):e31869. doi: 10.1371/journal.pone.0031869. Epub 2012 Mar 19.
Amyloid-like plaques are characteristic lesions defining the neuropathology of Alzheimer's disease (AD). The size and density of these plaques are closely associated with cognitive decline. To combat this disease, the few therapies that are available rely on drugs that increase neurotransmission; however, this approach has had limited success as it has simply slowed an imminent decline and failed to target the root cause of AD. Amyloid-like deposits result from aggregation of the Aβ peptide, and thus, reducing amyloid burden by preventing Aβ aggregation represents an attractive approach to improve the therapeutic arsenal for AD. Recent studies have shown that the natural product curcumin is capable of crossing the blood-brain barrier in the CNS in sufficient quantities so as to reduce amyloid plaque burden. Based upon this bioactivity, we hypothesized that curcumin presents molecular features that make it an excellent lead compound for the development of more effective inhibitors of Aβ aggregation. To explore this hypothesis, we screened a library of curcumin analogs and identified structural features that contribute to the anti-oligomerization activity of curcumin and its analogs. First, at least one enone group in the spacer between aryl rings is necessary for measureable anti-Aβ aggregation activity. Second, an unsaturated carbon spacer between aryl rings is essential for inhibitory activity, as none of the saturated carbon spacers showed any margin of improvement over that of native curcumin. Third, methoxyl and hydroxyl substitutions in the meta- and para-positions on the aryl rings appear necessary for some measure of improved inhibitory activity. The best lead inhibitors have either their meta- and para-substituted methoxyl and hydroxyl groups reversed from that of curcumin or methoxyl or hydroxyl groups placed in both positions. The simple substitution of the para-hydroxy group on curcumin with a methoxy substitution improved inhibitor function by 6-7-fold over that measured for curcumin.
淀粉样斑块是定义阿尔茨海默病(AD)神经病理学的特征性病变。这些斑块的大小和密度与认知能力下降密切相关。为了治疗这种疾病,目前可用的少数疗法依赖于增加神经递质传递的药物;然而,由于这种方法只是减缓了即将发生的衰退,未能针对 AD 的根本原因,因此收效甚微。淀粉样样沉积物是由 Aβ肽聚集产生的,因此,通过防止 Aβ聚集来减少淀粉样蛋白负担代表了改善 AD 治疗武器库的一种有吸引力的方法。最近的研究表明,天然产物姜黄素能够以足够的量穿过血脑屏障进入中枢神经系统,从而减少淀粉样斑块负担。基于这种生物活性,我们假设姜黄素具有使其成为更有效的 Aβ聚集抑制剂开发的优秀先导化合物的分子特征。为了探索这一假设,我们筛选了姜黄素类似物文库,并确定了有助于姜黄素及其类似物抗寡聚化活性的结构特征。首先,芳环之间的间隔物中至少有一个烯酮基团对于可测量的抗 Aβ聚集活性是必需的。其次,芳环之间的不饱和碳间隔物对于抑制活性是必不可少的,因为所有饱和碳间隔物都没有比天然姜黄素表现出任何改善的余地。第三,芳环上间位和对位的甲氧基和羟基取代对于提高抑制活性是必要的。最好的先导抑制剂要么具有与姜黄素相反的间位和对位甲氧基和羟基取代,要么具有在两个位置上的甲氧基或羟基取代。将姜黄素的对位羟基简单地用甲氧基取代,可将抑制剂功能提高 6-7 倍,超过姜黄素的测量值。